Single-nucleus Ribonucleic Acid-sequencing and Spatial Transcriptomics Reveal the Cardioprotection of Shexiang Baoxin Pill (MUSKARDIA) in Mice with Myocardial Ischemia-Reperfusion Injury

The Shexiang Baoxin Pill (MUSKARDIA) has been extensively used to treat cardiovascular diseases in China for four decades, and its clinical efficacy has been widely approved. However, the mechanism by which this is achieved remains largely unexplored. Research attempting to understand the underlying mechanism is ongoing, but the findings are controversial. Here, we aimed to explore the possible mechanism of MUSKARDIA in myocardial ischemia-reperfusion (I/R) injury using heart single-nucleus and spatial ribonucleic acid (RNA) sequencing. Heart tissues of C57BL/6 mice were isolated from sham, I/R, and MUSKARDIA groups and analyzed using scRNAseq.

麝香保心丸（MUSKARDIA）在我国四十年来被广泛应用于心血管疾病的治疗，其临床疗效已得到广泛认可。然而，其发挥治疗作用的具体机制仍未得到充分阐释。当前针对其潜在作用机制的研究仍在推进，但所得结论尚存争议。本研究拟借助心脏单细胞核及空间核糖核酸（RNA）测序技术，探究麝香保心丸（MUSKARDIA）在心肌缺血再灌注（I/R）损伤中的潜在作用机制。研究人员从假手术组、缺血再灌注组及麝香保心丸组的C57BL/6小鼠中分离心脏组织，并通过单细胞RNA测序（scRNAseq）完成相关分析。